

# Richard J P Brown

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3972198/richard-j-p-brown-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59  
papers

1,805  
citations

24  
h-index

42  
g-index

61  
ext. papers

2,096  
ext. citations

8  
avg, IF

4.2  
L-index

#	Paper	IF	Citations
59	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance.. <i>Virus Evolution</i> , <b>2022</b> , 8, veac007	3.7	1
58	The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection.. <i>Journal of Virology</i> , <b>2022</b> , e0199521	6.6	0
57	Single-cell analysis of arthritogenic alphavirus-infected human synovial fibroblasts links low abundance of viral RNA to induction of innate immunity and arthralgia-associated gene expression. <i>Emerging Microbes and Infections</i> , <b>2021</b> , 10, 2151-2168	18.9	2
56	Initial HCV infection of adult hepatocytes triggers a temporally structured transcriptional program containing diverse pro- and anti-viral elements. <i>Journal of Virology</i> , <b>2021</b> ,	6.6	3
55	Strategies to Inhibit Hepatitis B Virus at the Transcript Level. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
54	Generation of hiPSC-derived low threshold mechanoreceptors containing axonal termini resembling bulbous sensory nerve endings and expressing Piezo1 and Piezo2. <i>Stem Cell Research</i> , <b>2021</b> , 56, 102535	1.6	1
53	Liver-expressed and limit hepatitis C virus cross-species transmission to mice. <i>Science Advances</i> , <b>2020</b> , 6,	14.3	9
52	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. <i>Gut</i> , <b>2020</b> , 69, 1659-1666	19.2	5
51	C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 549-558	13.4	10
50	Hepatitis C Virus. <i>Trends in Microbiology</i> , <b>2019</b> , 27, 379-380	12.4	21
49	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. <i>Cells</i> , <b>2019</b> , 8,	7.9	2
48	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1082-1092	13.4	12
47	Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. <i>Viruses</i> , <b>2019</b> , 11,	6.2	7
46	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 593-602	13.4	11
45	Hepatitis E virus replication and interferon responses in human placental cells. <i>Hepatology Communications</i> , <b>2018</b> , 2, 173-187	6	26
44	Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease. <i>Antimicrobial Resistance and Infection Control</i> , <b>2018</b> , 7, 21	6.2	1
43	Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. <i>Antiviral Research</i> , <b>2018</b> , 160, 25-37	10.8	4

42	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. <i>Antiviral Research</i> , <b>2017</b> , 139, 129-137	10.8	4
41	Exacerbation d'infection par le virus de l'hépatite E au cours d'un traitement par anti-TNF. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2017</b> , 84, 244-247	0.1	
40	Immune protection against reinfection with nonprimate hepacivirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E2430-E2439	11.5	36
39	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	15
38	Exacerbation of hepatitis E virus infection during anti-TNF treatment. <i>Joint Bone Spine</i> , <b>2017</b> , 84, 217-219.	9	6
37	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. <i>Gut</i> , <b>2016</b> , 65, 2029-2034	19.2	16
36	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. <i>Journal of Virology</i> , <b>2016</b> , 90, 5075-5089	6.6	4
35	Vertical transmission of hepatitis C virus-like non-primate hepacivirus in horses. <i>Journal of General Virology</i> , <b>2016</b> , 97, 2540-2551	4.9	19
34	Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations. <i>Viruses</i> , <b>2016</b> , 8,	6.2	35
33	Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. <i>Hepatology</i> , <b>2016</b> , 63, 49-62	11.2	53
32	Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 361-8	7	37
31	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , <b>2016</b> , 65, 1733-43.	19.2	101
30	Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. <i>Journal of Virology</i> , <b>2016</b> , 90, 10670-10681	6.6	17
29	A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. <i>Journal of Virology</i> , <b>2015</b> , 90, 3288-301	6.6	47
28	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. <i>Viruses</i> , <b>2015</b> , 7, 3995-4046	6.2	38
27	Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses. <i>Hepatology</i> , <b>2015</b> , 61, 447-59	11.2	99
26	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. <i>Gut</i> , <b>2014</b> , 63, 1137-49	19.2	119
25	Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. <i>Antiviral Research</i> , <b>2014</b> , 110, 52-9	10.8	10

24	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. <i>Hepatology</i> , <b>2014</b> , 60, 508-20	11.2	7
23	Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. <i>Journal of Innate Immunity</i> , <b>2014</b> , 6, 676-84	6.9	25
22	Natural reservoirs for homologs of hepatitis C virus. <i>Emerging Microbes and Infections</i> , <b>2014</b> , 3, e21	18.9	65
21	Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. <i>Journal of Virology</i> , <b>2014</b> , 88, 667-78	6.6	2
20	Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. <i>Hepatology</i> , <b>2014</b> , 59, 78-88	11.2	34
19	Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies. <i>Journal of General Virology</i> , <b>2014</b> , 95, 66-70	4.9	2
18	Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 174, 265-73	6.2	16
17	An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. <i>Hepatology</i> , <b>2013</b> , 58, 932-9	11.2	56
16	Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment. <i>Journal of Virology</i> , <b>2013</b> , 87, 13297-306	6.6	18
15	Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. <i>Journal of Virology</i> , <b>2012</b> , 86, 11956-66	6.6	30
14	Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. <i>Journal of Virology</i> , <b>2012</b> , 86, 2739-49	6.6	48
13	Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. <i>Journal of Virology</i> , <b>2011</b> , 85, 4246-57	6.6	46
12	A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine. <i>CKJ: Clinical Kidney Journal</i> , <b>2011</b> , 4, 32-5	4.5	4
11	Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. <i>Journal of Virology</i> , <b>2011</b> , 85, 6024-37	6.6	44
10	Acute hepatitis C virus infection: a dynamic-and challenging-concept. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202, 1765-7	7	8
9	Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. <i>Future Virology</i> , <b>2010</b> , 5, 435-451	2.4	19
8	Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. <i>Retrovirology</i> , <b>2008</b> , 5, 5	3.6	69
7	Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. <i>Journal of General Virology</i> , <b>2007</b> , 88, 2991-3001	4.9	56

6	Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. <i>Journal of General Virology</i> , <b>2007</b> , 88, 458-469	4.9	23
5	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. <i>Hepatology</i> , <b>2006</b> , 43, 592-601	11.2	132
4	Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. <i>Journal of Virology</i> , <b>2006</b> , 80, 6324-32	6.6	89
3	Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. <i>Journal of Virology</i> , <b>2006</b> , 80, 8695-704	6.6	204
2	Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. <i>Journal of General Virology</i> , <b>2005</b> , 86, 1931-1942	4.9	33
1	Single-cell transcriptomic analysis of antiviral responses and viral antagonism in Chikungunya virus-infected synovial fibroblasts		3